English
简体中文
Total: £ 56.28
Published Date: 2025-09-17 | Pages: 92 | Tables: 89 | Pharma & Healthcare
The global market for Quick Reliever Medicines for Asthma and COPD was valued at US$ 4865 million in the year 2024 and is projected to reach a revised size of US$ 6409 million by 2031, growing at a CAGR of 4.2% during the forecast period.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Quick Reliever Medicines for Asthma and COPD competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Quick reliever medicines for asthma and COPD primarily consist of short-acting β2-agonists (such as salbutamol) and anticholinergic agents, with upstream supply chains including active pharmaceutical ingredients (APIs), excipients, and propellants for inhalation formulations. The upstream is dominated by large international API manufacturers and specialized excipient suppliers, while production is led by multinational pharmaceutical companies and regional manufacturers. Downstream customers mainly include hospitals, retail pharmacies, and long-term patients with chronic respiratory diseases. As these medicines are essential for acute symptom relief, market demand remains stable and rigid.
In 2024, the global average price of quick reliever medicines for asthma and COPD is approximately USD 20.3 per unit, with total sales reaching around 239 million units.
North American market for Quick Reliever Medicines for Asthma and COPD is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Quick Reliever Medicines for Asthma and COPD is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Quick Reliever Medicines for Asthma and COPD include Boehringer Ingelheim, GSK, Teva Pharmaceutical, Prasco Laboratories, Cipla, Lupin Laboratories, Laboratorio Aldo-Union, Polpharma, Jewim Pharmaceutical, Heilongjiang Fulekang Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Quick Reliever Medicines for Asthma and COPD, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Quick Reliever Medicines for Asthma and COPD.
The Quick Reliever Medicines for Asthma and COPD market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Quick Reliever Medicines for Asthma and COPD market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Quick Reliever Medicines for Asthma and COPD manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Boehringer Ingelheim
GSK
Teva Pharmaceutical
Prasco Laboratories
Cipla
Lupin Laboratories
Laboratorio Aldo-Union
Polpharma
Jewim Pharmaceutical
Heilongjiang Fulekang Pharmaceutical
Shanghai Pharmaceuticals
Lunan Better Pharmaceutical
China Resources Double Crane Pharmaceutical
Segment by Type
Short-Acting Beta2-Agonists (SABA)
Short-Acting Muscarinic Antagonists (SAMA)
SABA-ICS
SABA-SAMA
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Quick Reliever Medicines for Asthma and COPD manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Quick Reliever Medicines for Asthma and COPD in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Quick Reliever Medicines for Asthma and COPD Market Overview
1.1 Product Definition
1.2 Quick Reliever Medicines for Asthma and COPD by Type
1.2.1 Global Quick Reliever Medicines for Asthma and COPD Market Value Comparison by Type (2024 VS 2031)
1.2.2 Short-Acting Beta2-Agonists (SABA)
1.2.3 Short-Acting Muscarinic Antagonists (SAMA)
1.2.4 SABA-ICS
1.2.5 SABA-SAMA
1.3 Quick Reliever Medicines for Asthma and COPD by Application
1.3.1 Global Quick Reliever Medicines for Asthma and COPD Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Quick Reliever Medicines for Asthma and COPD Market Size Estimates and Forecasts
1.4.1 Global Quick Reliever Medicines for Asthma and COPD Revenue 2020-2031
1.4.2 Global Quick Reliever Medicines for Asthma and COPD Sales 2020-2031
1.4.3 Global Quick Reliever Medicines for Asthma and COPD Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Quick Reliever Medicines for Asthma and COPD Market Competition by Manufacturers
2.1 Global Quick Reliever Medicines for Asthma and COPD Sales Market Share by Manufacturers (2020-2025)
2.2 Global Quick Reliever Medicines for Asthma and COPD Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Quick Reliever Medicines for Asthma and COPD Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Quick Reliever Medicines for Asthma and COPD, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Quick Reliever Medicines for Asthma and COPD, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Quick Reliever Medicines for Asthma and COPD, Product Type & Application
2.7 Global Key Manufacturers of Quick Reliever Medicines for Asthma and COPD, Date of Enter into This Industry
2.8 Global Quick Reliever Medicines for Asthma and COPD Market Competitive Situation and Trends
2.8.1 Global Quick Reliever Medicines for Asthma and COPD Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Quick Reliever Medicines for Asthma and COPD Players Market Share by Revenue
2.8.3 Global Quick Reliever Medicines for Asthma and COPD Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Quick Reliever Medicines for Asthma and COPD Market Scenario by Region
3.1 Global Quick Reliever Medicines for Asthma and COPD Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Quick Reliever Medicines for Asthma and COPD Sales by Region: 2020-2031
3.2.1 Global Quick Reliever Medicines for Asthma and COPD Sales by Region: 2020-2025
3.2.2 Global Quick Reliever Medicines for Asthma and COPD Sales by Region: 2026-2031
3.3 Global Quick Reliever Medicines for Asthma and COPD Revenue by Region: 2020-2031
3.3.1 Global Quick Reliever Medicines for Asthma and COPD Revenue by Region: 2020-2025
3.3.2 Global Quick Reliever Medicines for Asthma and COPD Revenue by Region: 2026-2031
3.4 North America Quick Reliever Medicines for Asthma and COPD Market Facts & Figures by Country
3.4.1 North America Quick Reliever Medicines for Asthma and COPD Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Quick Reliever Medicines for Asthma and COPD Sales by Country (2020-2031)
3.4.3 North America Quick Reliever Medicines for Asthma and COPD Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Quick Reliever Medicines for Asthma and COPD Market Facts & Figures by Country
3.5.1 Europe Quick Reliever Medicines for Asthma and COPD Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Quick Reliever Medicines for Asthma and COPD Sales by Country (2020-2031)
3.5.3 Europe Quick Reliever Medicines for Asthma and COPD Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Quick Reliever Medicines for Asthma and COPD Market Facts & Figures by Region
3.6.1 Asia Pacific Quick Reliever Medicines for Asthma and COPD Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Quick Reliever Medicines for Asthma and COPD Sales by Region (2020-2031)
3.6.3 Asia Pacific Quick Reliever Medicines for Asthma and COPD Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Quick Reliever Medicines for Asthma and COPD Market Facts & Figures by Country
3.7.1 Latin America Quick Reliever Medicines for Asthma and COPD Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Quick Reliever Medicines for Asthma and COPD Sales by Country (2020-2031)
3.7.3 Latin America Quick Reliever Medicines for Asthma and COPD Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Quick Reliever Medicines for Asthma and COPD Market Facts & Figures by Country
3.8.1 Middle East and Africa Quick Reliever Medicines for Asthma and COPD Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Quick Reliever Medicines for Asthma and COPD Sales by Country (2020-2031)
3.8.3 Middle East and Africa Quick Reliever Medicines for Asthma and COPD Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Quick Reliever Medicines for Asthma and COPD Sales by Type (2020-2031)
4.1.1 Global Quick Reliever Medicines for Asthma and COPD Sales by Type (2020-2025)
4.1.2 Global Quick Reliever Medicines for Asthma and COPD Sales by Type (2026-2031)
4.1.3 Global Quick Reliever Medicines for Asthma and COPD Sales Market Share by Type (2020-2031)
4.2 Global Quick Reliever Medicines for Asthma and COPD Revenue by Type (2020-2031)
4.2.1 Global Quick Reliever Medicines for Asthma and COPD Revenue by Type (2020-2025)
4.2.2 Global Quick Reliever Medicines for Asthma and COPD Revenue by Type (2026-2031)
4.2.3 Global Quick Reliever Medicines for Asthma and COPD Revenue Market Share by Type (2020-2031)
4.3 Global Quick Reliever Medicines for Asthma and COPD Price by Type (2020-2031)
5 Segment by Application
5.1 Global Quick Reliever Medicines for Asthma and COPD Sales by Application (2020-2031)
5.1.1 Global Quick Reliever Medicines for Asthma and COPD Sales by Application (2020-2025)
5.1.2 Global Quick Reliever Medicines for Asthma and COPD Sales by Application (2026-2031)
5.1.3 Global Quick Reliever Medicines for Asthma and COPD Sales Market Share by Application (2020-2031)
5.2 Global Quick Reliever Medicines for Asthma and COPD Revenue by Application (2020-2031)
5.2.1 Global Quick Reliever Medicines for Asthma and COPD Revenue by Application (2020-2025)
5.2.2 Global Quick Reliever Medicines for Asthma and COPD Revenue by Application (2026-2031)
5.2.3 Global Quick Reliever Medicines for Asthma and COPD Revenue Market Share by Application (2020-2031)
5.3 Global Quick Reliever Medicines for Asthma and COPD Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Boehringer Ingelheim
6.1.1 Boehringer Ingelheim Company Information
6.1.2 Boehringer Ingelheim Description and Business Overview
6.1.3 Boehringer Ingelheim Quick Reliever Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Boehringer Ingelheim Quick Reliever Medicines for Asthma and COPD Product Portfolio
6.1.5 Boehringer Ingelheim Recent Developments/Updates
6.2 GSK
6.2.1 GSK Company Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Quick Reliever Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.2.4 GSK Quick Reliever Medicines for Asthma and COPD Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Teva Pharmaceutical
6.3.1 Teva Pharmaceutical Company Information
6.3.2 Teva Pharmaceutical Description and Business Overview
6.3.3 Teva Pharmaceutical Quick Reliever Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Teva Pharmaceutical Quick Reliever Medicines for Asthma and COPD Product Portfolio
6.3.5 Teva Pharmaceutical Recent Developments/Updates
6.4 Prasco Laboratories
6.4.1 Prasco Laboratories Company Information
6.4.2 Prasco Laboratories Description and Business Overview
6.4.3 Prasco Laboratories Quick Reliever Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Prasco Laboratories Quick Reliever Medicines for Asthma and COPD Product Portfolio
6.4.5 Prasco Laboratories Recent Developments/Updates
6.5 Cipla
6.5.1 Cipla Company Information
6.5.2 Cipla Description and Business Overview
6.5.3 Cipla Quick Reliever Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Cipla Quick Reliever Medicines for Asthma and COPD Product Portfolio
6.5.5 Cipla Recent Developments/Updates
6.6 Lupin Laboratories
6.6.1 Lupin Laboratories Company Information
6.6.2 Lupin Laboratories Description and Business Overview
6.6.3 Lupin Laboratories Quick Reliever Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Lupin Laboratories Quick Reliever Medicines for Asthma and COPD Product Portfolio
6.6.5 Lupin Laboratories Recent Developments/Updates
6.7 Laboratorio Aldo-Union
6.7.1 Laboratorio Aldo-Union Company Information
6.7.2 Laboratorio Aldo-Union Description and Business Overview
6.7.3 Laboratorio Aldo-Union Quick Reliever Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Laboratorio Aldo-Union Quick Reliever Medicines for Asthma and COPD Product Portfolio
6.7.5 Laboratorio Aldo-Union Recent Developments/Updates
6.8 Polpharma
6.8.1 Polpharma Company Information
6.8.2 Polpharma Description and Business Overview
6.8.3 Polpharma Quick Reliever Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Polpharma Quick Reliever Medicines for Asthma and COPD Product Portfolio
6.8.5 Polpharma Recent Developments/Updates
6.9 Jewim Pharmaceutical
6.9.1 Jewim Pharmaceutical Company Information
6.9.2 Jewim Pharmaceutical Description and Business Overview
6.9.3 Jewim Pharmaceutical Quick Reliever Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Jewim Pharmaceutical Quick Reliever Medicines for Asthma and COPD Product Portfolio
6.9.5 Jewim Pharmaceutical Recent Developments/Updates
6.10 Heilongjiang Fulekang Pharmaceutical
6.10.1 Heilongjiang Fulekang Pharmaceutical Company Information
6.10.2 Heilongjiang Fulekang Pharmaceutical Description and Business Overview
6.10.3 Heilongjiang Fulekang Pharmaceutical Quick Reliever Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Heilongjiang Fulekang Pharmaceutical Quick Reliever Medicines for Asthma and COPD Product Portfolio
6.10.5 Heilongjiang Fulekang Pharmaceutical Recent Developments/Updates
6.11 Shanghai Pharmaceuticals
6.11.1 Shanghai Pharmaceuticals Company Information
6.11.2 Shanghai Pharmaceuticals Description and Business Overview
6.11.3 Shanghai Pharmaceuticals Quick Reliever Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Shanghai Pharmaceuticals Quick Reliever Medicines for Asthma and COPD Product Portfolio
6.11.5 Shanghai Pharmaceuticals Recent Developments/Updates
6.12 Lunan Better Pharmaceutical
6.12.1 Lunan Better Pharmaceutical Company Information
6.12.2 Lunan Better Pharmaceutical Description and Business Overview
6.12.3 Lunan Better Pharmaceutical Quick Reliever Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Lunan Better Pharmaceutical Quick Reliever Medicines for Asthma and COPD Product Portfolio
6.12.5 Lunan Better Pharmaceutical Recent Developments/Updates
6.13 China Resources Double Crane Pharmaceutical
6.13.1 China Resources Double Crane Pharmaceutical Company Information
6.13.2 China Resources Double Crane Pharmaceutical Description and Business Overview
6.13.3 China Resources Double Crane Pharmaceutical Quick Reliever Medicines for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)
6.13.4 China Resources Double Crane Pharmaceutical Quick Reliever Medicines for Asthma and COPD Product Portfolio
6.13.5 China Resources Double Crane Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Quick Reliever Medicines for Asthma and COPD Industry Chain Analysis
7.2 Quick Reliever Medicines for Asthma and COPD Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Quick Reliever Medicines for Asthma and COPD Production Mode & Process Analysis
7.4 Quick Reliever Medicines for Asthma and COPD Sales and Marketing
7.4.1 Quick Reliever Medicines for Asthma and COPD Sales Channels
7.4.2 Quick Reliever Medicines for Asthma and COPD Distributors
7.5 Quick Reliever Medicines for Asthma and COPD Customer Analysis
8 Quick Reliever Medicines for Asthma and COPD Market Dynamics
8.1 Quick Reliever Medicines for Asthma and COPD Industry Trends
8.2 Quick Reliever Medicines for Asthma and COPD Market Drivers
8.3 Quick Reliever Medicines for Asthma and COPD Market Challenges
8.4 Quick Reliever Medicines for Asthma and COPD Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Quick Reliever Medicines for Asthma and COPD Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Quick Reliever Medicines for Asthma and COPD Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Quick Reliever Medicines for Asthma and COPD Market Competitive Situation by Manufacturers in 2024
Table 4. Global Quick Reliever Medicines for Asthma and COPD Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Quick Reliever Medicines for Asthma and COPD Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Quick Reliever Medicines for Asthma and COPD Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Quick Reliever Medicines for Asthma and COPD Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Quick Reliever Medicines for Asthma and COPD Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Quick Reliever Medicines for Asthma and COPD, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Quick Reliever Medicines for Asthma and COPD, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Quick Reliever Medicines for Asthma and COPD, Product Type & Application
Table 12. Global Key Manufacturers of Quick Reliever Medicines for Asthma and COPD, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Quick Reliever Medicines for Asthma and COPD by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Quick Reliever Medicines for Asthma and COPD as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Quick Reliever Medicines for Asthma and COPD Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Quick Reliever Medicines for Asthma and COPD Sales by Region (2020-2025) & (K Units)
Table 18. Global Quick Reliever Medicines for Asthma and COPD Sales Market Share by Region (2020-2025)
Table 19. Global Quick Reliever Medicines for Asthma and COPD Sales by Region (2026-2031) & (K Units)
Table 20. Global Quick Reliever Medicines for Asthma and COPD Sales Market Share by Region (2026-2031)
Table 21. Global Quick Reliever Medicines for Asthma and COPD Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Quick Reliever Medicines for Asthma and COPD Revenue Market Share by Region (2020-2025)
Table 23. Global Quick Reliever Medicines for Asthma and COPD Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Quick Reliever Medicines for Asthma and COPD Revenue Market Share by Region (2026-2031)
Table 25. North America Quick Reliever Medicines for Asthma and COPD Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Quick Reliever Medicines for Asthma and COPD Sales by Country (2020-2025) & (K Units)
Table 27. North America Quick Reliever Medicines for Asthma and COPD Sales by Country (2026-2031) & (K Units)
Table 28. North America Quick Reliever Medicines for Asthma and COPD Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Quick Reliever Medicines for Asthma and COPD Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Quick Reliever Medicines for Asthma and COPD Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Quick Reliever Medicines for Asthma and COPD Sales by Country (2020-2025) & (K Units)
Table 32. Europe Quick Reliever Medicines for Asthma and COPD Sales by Country (2026-2031) & (K Units)
Table 33. Europe Quick Reliever Medicines for Asthma and COPD Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Quick Reliever Medicines for Asthma and COPD Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Quick Reliever Medicines for Asthma and COPD Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Quick Reliever Medicines for Asthma and COPD Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Quick Reliever Medicines for Asthma and COPD Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Quick Reliever Medicines for Asthma and COPD Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Quick Reliever Medicines for Asthma and COPD Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Quick Reliever Medicines for Asthma and COPD Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Quick Reliever Medicines for Asthma and COPD Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Quick Reliever Medicines for Asthma and COPD Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Quick Reliever Medicines for Asthma and COPD Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Quick Reliever Medicines for Asthma and COPD Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Quick Reliever Medicines for Asthma and COPD Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Quick Reliever Medicines for Asthma and COPD Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Quick Reliever Medicines for Asthma and COPD Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Quick Reliever Medicines for Asthma and COPD Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Quick Reliever Medicines for Asthma and COPD Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Quick Reliever Medicines for Asthma and COPD Sales (K Units) by Type (2020-2025)
Table 51. Global Quick Reliever Medicines for Asthma and COPD Sales (K Units) by Type (2026-2031)
Table 52. Global Quick Reliever Medicines for Asthma and COPD Sales Market Share by Type (2020-2025)
Table 53. Global Quick Reliever Medicines for Asthma and COPD Sales Market Share by Type (2026-2031)
Table 54. Global Quick Reliever Medicines for Asthma and COPD Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Quick Reliever Medicines for Asthma and COPD Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Quick Reliever Medicines for Asthma and COPD Revenue Market Share by Type (2020-2025)
Table 57. Global Quick Reliever Medicines for Asthma and COPD Revenue Market Share by Type (2026-2031)
Table 58. Global Quick Reliever Medicines for Asthma and COPD Price (US$/Unit) by Type (2020-2025)
Table 59. Global Quick Reliever Medicines for Asthma and COPD Price (US$/Unit) by Type (2026-2031)
Table 60. Global Quick Reliever Medicines for Asthma and COPD Sales (K Units) by Application (2020-2025)
Table 61. Global Quick Reliever Medicines for Asthma and COPD Sales (K Units) by Application (2026-2031)
Table 62. Global Quick Reliever Medicines for Asthma and COPD Sales Market Share by Application (2020-2025)
Table 63. Global Quick Reliever Medicines for Asthma and COPD Sales Market Share by Application (2026-2031)
Table 64. Global Quick Reliever Medicines for Asthma and COPD Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Quick Reliever Medicines for Asthma and COPD Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Quick Reliever Medicines for Asthma and COPD Revenue Market Share by Application (2020-2025)
Table 67. Global Quick Reliever Medicines for Asthma and COPD Revenue Market Share by Application (2026-2031)
Table 68. Global Quick Reliever Medicines for Asthma and COPD Price (US$/Unit) by Application (2020-2025)
Table 69. Global Quick Reliever Medicines for Asthma and COPD Price (US$/Unit) by Application (2026-2031)
Table 70. Boehringer Ingelheim Company Information
Table 71. Boehringer Ingelheim Description and Business Overview
Table 72. Boehringer Ingelheim Quick Reliever Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Boehringer Ingelheim Quick Reliever Medicines for Asthma and COPD Product
Table 74. Boehringer Ingelheim Recent Developments/Updates
Table 75. GSK Company Information
Table 76. GSK Description and Business Overview
Table 77. GSK Quick Reliever Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. GSK Quick Reliever Medicines for Asthma and COPD Product
Table 79. GSK Recent Developments/Updates
Table 80. Teva Pharmaceutical Company Information
Table 81. Teva Pharmaceutical Description and Business Overview
Table 82. Teva Pharmaceutical Quick Reliever Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Teva Pharmaceutical Quick Reliever Medicines for Asthma and COPD Product
Table 84. Teva Pharmaceutical Recent Developments/Updates
Table 85. Prasco Laboratories Company Information
Table 86. Prasco Laboratories Description and Business Overview
Table 87. Prasco Laboratories Quick Reliever Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Prasco Laboratories Quick Reliever Medicines for Asthma and COPD Product
Table 89. Prasco Laboratories Recent Developments/Updates
Table 90. Cipla Company Information
Table 91. Cipla Description and Business Overview
Table 92. Cipla Quick Reliever Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Cipla Quick Reliever Medicines for Asthma and COPD Product
Table 94. Cipla Recent Developments/Updates
Table 95. Lupin Laboratories Company Information
Table 96. Lupin Laboratories Description and Business Overview
Table 97. Lupin Laboratories Quick Reliever Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Lupin Laboratories Quick Reliever Medicines for Asthma and COPD Product
Table 99. Lupin Laboratories Recent Developments/Updates
Table 100. Laboratorio Aldo-Union Company Information
Table 101. Laboratorio Aldo-Union Description and Business Overview
Table 102. Laboratorio Aldo-Union Quick Reliever Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Laboratorio Aldo-Union Quick Reliever Medicines for Asthma and COPD Product
Table 104. Laboratorio Aldo-Union Recent Developments/Updates
Table 105. Polpharma Company Information
Table 106. Polpharma Description and Business Overview
Table 107. Polpharma Quick Reliever Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Polpharma Quick Reliever Medicines for Asthma and COPD Product
Table 109. Polpharma Recent Developments/Updates
Table 110. Jewim Pharmaceutical Company Information
Table 111. Jewim Pharmaceutical Description and Business Overview
Table 112. Jewim Pharmaceutical Quick Reliever Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Jewim Pharmaceutical Quick Reliever Medicines for Asthma and COPD Product
Table 114. Jewim Pharmaceutical Recent Developments/Updates
Table 115. Heilongjiang Fulekang Pharmaceutical Company Information
Table 116. Heilongjiang Fulekang Pharmaceutical Description and Business Overview
Table 117. Heilongjiang Fulekang Pharmaceutical Quick Reliever Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Heilongjiang Fulekang Pharmaceutical Quick Reliever Medicines for Asthma and COPD Product
Table 119. Heilongjiang Fulekang Pharmaceutical Recent Developments/Updates
Table 120. Shanghai Pharmaceuticals Company Information
Table 121. Shanghai Pharmaceuticals Description and Business Overview
Table 122. Shanghai Pharmaceuticals Quick Reliever Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. Shanghai Pharmaceuticals Quick Reliever Medicines for Asthma and COPD Product
Table 124. Shanghai Pharmaceuticals Recent Developments/Updates
Table 125. Lunan Better Pharmaceutical Company Information
Table 126. Lunan Better Pharmaceutical Description and Business Overview
Table 127. Lunan Better Pharmaceutical Quick Reliever Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. Lunan Better Pharmaceutical Quick Reliever Medicines for Asthma and COPD Product
Table 129. Lunan Better Pharmaceutical Recent Developments/Updates
Table 130. China Resources Double Crane Pharmaceutical Company Information
Table 131. China Resources Double Crane Pharmaceutical Description and Business Overview
Table 132. China Resources Double Crane Pharmaceutical Quick Reliever Medicines for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 133. China Resources Double Crane Pharmaceutical Quick Reliever Medicines for Asthma and COPD Product
Table 134. China Resources Double Crane Pharmaceutical Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Quick Reliever Medicines for Asthma and COPD Distributors List
Table 138. Quick Reliever Medicines for Asthma and COPD Customers List
Table 139. Quick Reliever Medicines for Asthma and COPD Market Trends
Table 140. Quick Reliever Medicines for Asthma and COPD Market Drivers
Table 141. Quick Reliever Medicines for Asthma and COPD Market Challenges
Table 142. Quick Reliever Medicines for Asthma and COPD Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
Table 146. Authors List of This Report
List of Figures
Figure 1. Product Picture of Quick Reliever Medicines for Asthma and COPD
Figure 2. Global Quick Reliever Medicines for Asthma and COPD Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Quick Reliever Medicines for Asthma and COPD Market Share by Type: 2024 & 2031
Figure 4. Short-Acting Beta2-Agonists (SABA) Product Picture
Figure 5. Short-Acting Muscarinic Antagonists (SAMA) Product Picture
Figure 6. SABA-ICS Product Picture
Figure 7. SABA-SAMA Product Picture
Figure 8. Global Quick Reliever Medicines for Asthma and COPD Market Value by Application (2020-2031) & (US$ Million)
Figure 9. Global Quick Reliever Medicines for Asthma and COPD Market Share by Application: 2024 & 2031
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Others
Figure 13. Global Quick Reliever Medicines for Asthma and COPD Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Quick Reliever Medicines for Asthma and COPD Market Size (2020-2031) & (US$ Million)
Figure 15. Global Quick Reliever Medicines for Asthma and COPD Sales (2020-2031) & (K Units)
Figure 16. Global Quick Reliever Medicines for Asthma and COPD Average Price (US$/Unit) & (2020-2031)
Figure 17. Quick Reliever Medicines for Asthma and COPD Report Years Considered
Figure 18. Quick Reliever Medicines for Asthma and COPD Sales Share by Manufacturers in 2024
Figure 19. Global Quick Reliever Medicines for Asthma and COPD Revenue Share by Manufacturers in 2024
Figure 20. Global 5 and 10 Largest Quick Reliever Medicines for Asthma and COPD Players: Market Share by Revenue in Quick Reliever Medicines for Asthma and COPD in 2024
Figure 21. Quick Reliever Medicines for Asthma and COPD Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 22. Global Quick Reliever Medicines for Asthma and COPD Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 23. North America Quick Reliever Medicines for Asthma and COPD Sales Market Share by Country (2020-2031)
Figure 24. North America Quick Reliever Medicines for Asthma and COPD Revenue Market Share by Country (2020-2031)
Figure 25. United States Quick Reliever Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Canada Quick Reliever Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 27. Europe Quick Reliever Medicines for Asthma and COPD Sales Market Share by Country (2020-2031)
Figure 28. Europe Quick Reliever Medicines for Asthma and COPD Revenue Market Share by Country (2020-2031)
Figure 29. Germany Quick Reliever Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. France Quick Reliever Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. U.K. Quick Reliever Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Italy Quick Reliever Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Russia Quick Reliever Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Asia Pacific Quick Reliever Medicines for Asthma and COPD Sales Market Share by Region (2020-2031)
Figure 35. Asia Pacific Quick Reliever Medicines for Asthma and COPD Revenue Market Share by Region (2020-2031)
Figure 36. China Quick Reliever Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. Japan Quick Reliever Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. South Korea Quick Reliever Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. India Quick Reliever Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Australia Quick Reliever Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. China Taiwan Quick Reliever Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Southeast Asia Quick Reliever Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Latin America Quick Reliever Medicines for Asthma and COPD Sales Market Share by Country (2020-2031)
Figure 44. Latin America Quick Reliever Medicines for Asthma and COPD Revenue Market Share by Country (2020-2031)
Figure 45. Mexico Quick Reliever Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Brazil Quick Reliever Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Argentina Quick Reliever Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Colombia Quick Reliever Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Middle East and Africa Quick Reliever Medicines for Asthma and COPD Sales Market Share by Country (2020-2031)
Figure 50. Middle East and Africa Quick Reliever Medicines for Asthma and COPD Revenue Market Share by Country (2020-2031)
Figure 51. Turkey Quick Reliever Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Saudi Arabia Quick Reliever Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. UAE Quick Reliever Medicines for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Global Sales Market Share of Quick Reliever Medicines for Asthma and COPD by Type (2020-2031)
Figure 55. Global Revenue Market Share of Quick Reliever Medicines for Asthma and COPD by Type (2020-2031)
Figure 56. Global Quick Reliever Medicines for Asthma and COPD Price (US$/Unit) by Type (2020-2031)
Figure 57. Global Sales Market Share of Quick Reliever Medicines for Asthma and COPD by Application (2020-2031)
Figure 58. Global Revenue Market Share of Quick Reliever Medicines for Asthma and COPD by Application (2020-2031)
Figure 59. Global Quick Reliever Medicines for Asthma and COPD Price (US$/Unit) by Application (2020-2031)
Figure 60. Quick Reliever Medicines for Asthma and COPD Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
